Global T-cell Acute Lymphoblastic Leukemia Treatment Market Share

Market Share of Global T-cell Acute Lymphoblastic Leukemia Treatment Industry

Currently, many private companies are focusing on the development and introduction of novel therapeutics. Additionally, extensive research and development activities are being initiated by most of the market players, government organizations and academic research institutes. Some of the key innovations in the market are: In 2017, Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration in specific gene, known as Capicua, has been inactivated and that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia.

T-Cell Acute Lymphoblastic Leukemia Treatment Market Leaders

1. Bristol Myer Squibb Company

2. Genmab A/S

3. Novartis AG

4. Pfizer Inc.

5. Kyowa Kirin Co., Ltd.

*Disclaimer: Major Players sorted in no particular order